The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinic...
Promise (mypromise.com): FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds
Source: Finanznachrichten.de
Read Full Story →
